Literature DB >> 16980198

Cortisol metabolism in hypertension.

Fabian Hammer1, Paul M Stewart.   

Abstract

Corticosteroids are critically involved in blood pressure regulation. Lack of adrenal steroids in Addison's disease causes life-threatening hypotension, whereas glucocorticoid excess in Cushing's syndrome invariably results in high blood pressure. At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action. By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol. Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia. Ingestion of competitive inhibitors of 11beta-HSD2 such as liquorice and carbenoxolone result in a similar but milder clinical phenotype. Epidemiological data suggests that polymorphic variability in the HSD11B2 gene determines salt sensitivity in the general population, which is a key predisposing factor to adult onset hypertension in some patients. Extrarenal sites of glucocorticoid action and metabolism that might impact on blood pressure include the vasculature and the central nervous system. Intriguingly, increased exposure to glucocorticoids during fetal life promotes high blood pressure in adulthood suggesting an early programming effect. Thus, metabolism and action in many peripheral tissues might contribute to the pathophysiology of human hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980198     DOI: 10.1016/j.beem.2006.07.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  25 in total

1.  LC-MS/MS Method for the Simultaneous Determination of Free Urinary Steroids.

Authors:  Fidel Allende; Sandra Solari; Carmen Campino; Cristian A Carvajal; Carlos F Lagos; Andrea Vecchiola; Carolina Valdivia; René Baudrand; Gareth I Owen; Carlos E Fardella
Journal:  Chromatographia       Date:  2014-02-11       Impact factor: 2.044

2.  Dexamethasone stimulates endothelin-1 gene expression in renal collecting duct cells.

Authors:  Lisa R Stow; George E Voren; Michelle L Gumz; Charles S Wingo; Brian D Cain
Journal:  Steroids       Date:  2011-12-19       Impact factor: 2.668

3.  Socioeconomic and race/ethnic differences in daily salivary cortisol profiles: the multi-ethnic study of atherosclerosis.

Authors:  Anjum Hajat; Ana Diez-Roux; Tracy G Franklin; Teresa Seeman; Sandi Shrager; Nalini Ranjit; Cecilia Castro; Karol Watson; Brisa Sanchez; Clemens Kirschbaum
Journal:  Psychoneuroendocrinology       Date:  2010-01-29       Impact factor: 4.905

4.  Licorice-induced apparent mineralocorticoid excess compounded by excessive use of terbutaline and high water intake.

Authors:  Laust Frisenberg Buhl; Frederik Nørregaard Pedersen; Marianne Skovsager Andersen; Dorte Glintborg
Journal:  BMJ Case Rep       Date:  2018-04-19

5.  Hypothalamic-pituitary-adrenal-axis dysregulation and double product increases potentiate ischemic heart disease risk in a Black male cohort: the SABPA study.

Authors:  Leoné Malan; Christiaan E Schutte; Ala'a Alkerwi; Saverio Stranges; Nicolaas T Malan
Journal:  Hypertens Res       Date:  2017-02-09       Impact factor: 3.872

6.  Orexins stimulate steroidogenic acute regulatory protein expression through multiple signaling pathways in human adrenal H295R cells.

Authors:  Manjunath Ramanjaneya; Alex C Conner; Jing Chen; Peter R Stanfield; Harpal S Randeva
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

7.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

8.  Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress.

Authors:  Andrea G Bechtold; Gina Patel; Guenther Hochhaus; Deborah A Scheuer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-11       Impact factor: 3.619

Review 9.  Developmental programming of cardiovascular disorders: focus on hypertension.

Authors:  Sheba M J MohanKumar; Andrew King; Andrew C Shin; Madhu P Sirivelu; P S MohanKumar; Gregory D Fink
Journal:  Rev Endocr Metab Disord       Date:  2007-08-01       Impact factor: 6.514

10.  11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.

Authors:  Lama Ghazi; Tanja Dudenbostel; Maria El Hachem; Mohammed Siddiqui; Chee Paul Lin; Suzanne Oparil; David A Calhoun
Journal:  Am J Hypertens       Date:  2017-05-01       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.